Only several hypoglycemic drugs, such as insulin sensitizer thiazolidinediones, are recommended for the treatment of biopsy-proven NASH by the American Association for the Study of Liver Disease (Chalasani et al., 2017). This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.